Vanguard: can it keep playing disruptor?

Vanguard: can it keep playing disruptor?

Vanguard became a powerhouse money manager thanks to a commitment to the philosophy of founder Jack Bogle. Now, with a new chief executive, can the firm push into other areas of financial services and reshape those too? The FT’s US managing editor Brooke Masters explains how the company’s guiding mantra could help or hinder these plans. Clips from CNBC


- - - - - - - - - - - - - - - - - - - - - - - - - -

For further reading:

How Vanguard plans to play disruptor again

Vanguard puts pressure on rivals with large round of fee cuts

Vanguard plans fresh push into active fixed-income market

- - - - - - - - - - - - - - - - - - - - - - - - - -


Follow Brooke Masters on X (@brookeamasters), or on Bluesky (@brookeamasters.ft.com) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more.


Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.

Episoder(319)

KKR, Bain and private equity’s push into Japan

KKR, Bain and private equity’s push into Japan

When international private equity groups first entered Japan at the turn of the 21st century, newspapers criticised them as vulture funds and politicians steered clear of public contact. Today, it’s a...

26 Nov 202521min

Coming soon from Tech Tonic: Defying death

Coming soon from Tech Tonic: Defying death

Investors are spending billions of dollars on novel ways to extend human life through inventive treatments, therapies, and even manipulating our genes. And increasingly, it seems as though anti-ageing...

24 Nov 20251min

What’s the deal with OpenAI's deals?

What’s the deal with OpenAI's deals?

OpenAI is entering a new era. It's restructured to add a for-profit arm to its business and has signed more than a trillion dollars’ worth of deals to secure chips and build out data centres. But thos...

19 Nov 202526min

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multib...

12 Nov 202526min

The $17bn nuclear start-up without any revenue

The $17bn nuclear start-up without any revenue

Publicly-listed Oklo sits at the intersection of two hot areas for Wall Street: artificial intelligence and energy companies. This year alone, Oklo’s share price has jumped more than 400 per cent. But...

5 Nov 202523min

$12bn of debt: How First Brands Group collapsed

$12bn of debt: How First Brands Group collapsed

Some of the world’s biggest financial institutions are reeling after the collapse of a little-known car parts supplier: First Brands Group. The company filed for bankruptcy last month, and since then,...

29 Okt 202526min

Can the world’s largest listed hedge fund rebound?

Can the world’s largest listed hedge fund rebound?

The world’s largest listed hedge fund manager, Man Group, is at a crossroads. After years of high flying thanks to its innovative quant trading strategies, the company’s hedge fund unit has been falte...

22 Okt 202519min

Introducing Untold: Toxic Legacy

Introducing Untold: Toxic Legacy

Introducing Toxic Legacy, a new season of Untold from the Financial Times. Host Laura Hughes uncovers a lead poisoning epidemic across the UK. You might be living with lead and not know it: the toxin ...

16 Okt 20252min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
e24-podden
rss-borsmorgen-okonominyhetene
rss-penger-polser-og-politikk
pengepodden-2
livet-pa-veien-med-jan-erik-larssen
finansredaksjonen
utbytte
pengesnakk
stormkast-med-valebrokk-stordalen
tid-er-penger-en-podcast-med-peter-warren
morgenkaffen-med-finansavisen
liberal-halvtime
rss-sunn-okonomi
lederpodden
rss-pa-konto
rss-investering-gjort-enkelt
rss-markedspuls-2